Experiences with metoprolol Durules, a slow-release formulation in hypertension.
The antihypertensive effect and the tolerability of metoprolol Durules have been studied in fifty-five patients with mild to moderate hypertension. The patients' diastolic blood pressure was greater than or equal to 95 mm Hg in order to qualify for entry. Thirty-seven out of fifty-three patients completing the study (70%) were treated with metoprolol Durules monotherapy throughout the study. The mean blood pressure was reduced from 153/101 to 138/92 mm Hg after metoprolol Durules compared to placebo (p less than 0.001). Twenty-seven patients received one Durules daily and ten patients received two Durules daily as the final dose. Of the sixteen patients not responding on metoprolol Durules, six patients achieved satisfactory control, i.e. a diastolic blood pressure below 95 mm Hg, when given 200 mg metoprolol + 25 mg hydrochlorothiazide (HCT). The results indicate that most patients with mild or moderate hypertension can be controlled with metoprolol Durules monotherapy given one daily. The addition of HCT gives a significant benefit in moderate hypertension, where metoprolol monotherapy is not sufficient.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008790:Metoprolol / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D011412:Propanolamines; D006852:Hydrochlorothiazide; D008790:Metoprolol